Russell Investments Group Ltd. Raises Stake in AngioDynamics, Inc. (NASDAQ:ANGO)

Russell Investments Group Ltd. boosted its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 133.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 24,979 shares of the medical instruments supplier’s stock after buying an additional 14,274 shares during the period. Russell Investments Group Ltd.’s holdings in AngioDynamics were worth $229,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. State Street Corp raised its stake in shares of AngioDynamics by 2.7% in the 3rd quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock valued at $6,305,000 after acquiring an additional 21,218 shares during the period. Barclays PLC raised its position in AngioDynamics by 81.0% in the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock valued at $651,000 after purchasing an additional 37,394 shares during the period. Geode Capital Management LLC raised its position in AngioDynamics by 5.1% in the third quarter. Geode Capital Management LLC now owns 960,767 shares of the medical instruments supplier’s stock valued at $7,477,000 after purchasing an additional 46,409 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of AngioDynamics by 28.7% during the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock worth $4,304,000 after purchasing an additional 123,271 shares in the last quarter. Finally, Moody National Bank Trust Division boosted its position in shares of AngioDynamics by 70.2% in the fourth quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier’s stock worth $511,000 after buying an additional 23,003 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $16.00 price target (up from $15.00) on shares of AngioDynamics in a research report on Monday, April 7th.

AngioDynamics Trading Up 3.1 %

Shares of ANGO stock opened at $9.64 on Friday. The firm has a fifty day simple moving average of $9.58 and a 200-day simple moving average of $9.09. The company has a market capitalization of $391.45 million, a PE ratio of -1.71 and a beta of 0.52. AngioDynamics, Inc. has a twelve month low of $5.47 and a twelve month high of $13.50.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The company had revenue of $72.00 million during the quarter, compared to analysts’ expectations of $70.30 million. The firm’s revenue was down 4.3% on a year-over-year basis. Equities research analysts predict that AngioDynamics, Inc. will post -0.37 EPS for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.